# A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer

> **NCT04236362** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Gynecological Cancer

## Interventions

- **DRUG:** TQB2450
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04236362
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-27
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-05-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2021-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04236362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04236362, "A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04236362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*